An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease (NCT00745615), a randomized phase 2 study. The primary outcome is Double-Blind Extension Period: Number of Participants With Adverse Events (AEs).

2. Clinical Question

This is an extension study, so the comparison groups reflect both participants’ earlier study assignments and their subsequent extension treatment. The registry describes the study as randomized, double-blind, and parallel-group, but the extension design includes participants continuing previous active treatment as well as participants previously receiving placebo who entered new blinded laquinimod assignments. The clinical question is therefore not the same as a fresh comparison of laquinimod against a concurrent placebo group across the full study population.

The record reports 257 enrolled participants. Its brief summary describes the double-blind phase as lasting up to Week 36, followed by an open-label phase that continued while the sponsor continued development of laquinimod for relapsing remitting multiple sclerosis or until early discontinuation. The open-label phase has no placebo comparator, and its observations should be read separately from the blinded-phase comparisons.

3. Trial Design

The registry identifies this as a Phase 2, randomized, double-blind, parallel-group active extension study of LAQ/5062. Its stated condition was relapsing remitting multiple sclerosis. The sponsor was Teva Pharmaceutical Industries, Ltd. The study enrolled 257 participants and is listed as terminated.

In the first phase, participants from active-treatment arms in LAQ/5062 continued their assigned treatment in blinded fashion. Participants assigned placebo in LAQ/5062 were randomized in blinded fashion to laquinimod 0.3 mg or laquinimod 0.6 mg. The four double-blind groups posted for the primary outcome are laquinimod 0.3 mg, laquinimod 0.6 mg, placebo/laquinimod 0.3 mg, and placebo/laquinimod 0.6 mg. The latter two labels indicate that participants entered the extension from placebo and then received the listed laquinimod dose.

After the double-blind phase ended, participants entered an open-label phase receiving laquinimod 0.6 mg daily. Participants who had received 0.3 mg in the double-blind phase also moved to 0.6 mg. The record says this phase continued until termination while the sponsor continued development, or until early discontinuation.

The registry lists baseline to Week 36 as the primary endpoint timeframe. Secondary outcomes include relapse counts, relapse-free participants, and magnetic resonance imaging lesion outcomes during the double-blind phase. The record does not report the randomization procedure, allocation concealment details, planned enrollment rationale, or the sponsor’s original statistical design assumptions. It also does not describe the reasons for termination.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Double-blind extension: Participants treated with placebo in LAQ/5062 study were equally randomized to one of 2 groups: Laquinimod 0.6 mg or Laquinimod 0.3 mg. Participants previously treated with laquinimod 0.6 mg or laquinimod 0.3 mg continued on their original treatment. Open-label extension: All participants received laquinimod 0.6 mg.

Double-Blind Extension (36 Weeks)

Reasons for not completing this period:

Open-Label (up to Approx 10.5 Years)

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: ITT analysis set included all participants who entered in extension study LAQ/5063 (after completion of the entire treatment period in LAQ/5062) and received at least one dose of laquinimod (either 0.3 mg or 0.6 mg) during the active double-blind phase.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Intent-to-treat (ITT) analysis set included all participants who entered in extension study LAQ/5063 (after completion of the entire treatment period in LAQ/5062) and received at least one dose of laquinimod (either 0.3 mg or 0.6 mg) during the active double-blind phase.

6. Primary Endpoint

The registry lists the primary outcome as Double-Blind Extension Period: Number of Participants With Adverse Events (AEs), measured over Baseline (Week 0) to Week 36.

The primary endpoint is the number of participants with adverse events during the double-blind extension from baseline, Week 0, to Week 36. An adverse event was defined as an untoward medical occurrence in a participant who received study drug, without regard to whether it might have been caused by the drug. The endpoint therefore counts events by participant and does not, by itself, establish causation.

The registry definition includes both serious and non-serious adverse events. A serious adverse event was one that resulted in death, initial or prolonged inpatient hospitalization, a life-threatening experience, persistent or significant disability or incapacity, or a congenital anomaly, or was considered significant for another reason. The record directs readers to its reported adverse-event section for summaries of other non-serious events and all serious events, regardless of causality.

Counting participants with at least one event is a straightforward way to describe how many people experienced an adverse event during the specified period. It differs from counting the total number of event episodes: a participant with more than one event still contributes one participant to this endpoint. The registry does not report the number of recurrent events per participant as part of this primary measure.

The stated analysis population includes participants who entered LAQ/5063 after completing the entire LAQ/5062 treatment period and received at least one dose of either laquinimod dose during the active double-blind phase. This definition matters when interpreting the group counts: they apply to the stated extension safety population, rather than automatically representing every person enrolled in the original study.

7. Results Posted in the Registry

• Double-Blind: Laquinimod 0.3 mg: 71.2% (57/80) versus 59.0% (23/39) on control; risk difference 12.3 percentage points (95% CI -6.1 to 30.6), risk ratio 1.21 (0.90–1.63); unadjusted two-proportion z-test p = 0.181.
• Double-Blind: Laquinimod 0.6 mg: 70.2% (66/94) versus 59.0% (23/39) on control; risk difference 11.2 percentage points (95% CI -6.8 to 29.2), risk ratio 1.19 (0.89–1.60); unadjusted two-proportion z-test p = 0.210.
• Double-Blind: Placebo/Laquinimod 0.6 mg: 72.7% (32/44) versus 59.0% (23/39) on control; risk difference 13.8 percentage points (95% CI -6.5 to 34.0), risk ratio 1.23 (0.90–1.70); unadjusted two-proportion z-test p = 0.186.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Double-Blind Period: Relapse Rate: Total Number of Confirmed Relapses

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Double-Blind: Laquinimod 0.3 mg: mean 0.39 versus 0.38 on control; difference 0.01 (95% CI -0.22 to 0.24), standardized effect d = 0.02; z-test p = 0.931.
  • Double-Blind: Laquinimod 0.6 mg: mean 0.36 versus 0.38 on control; difference -0.02 (95% CI -0.23 to 0.19), standardized effect d = -0.04; z-test p = 0.849.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Double-Blind: Laquinimod 0.3 mg and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Double-Blind: Laquinimod 0.6 mg and the control. The interval gives the range of effects that remain compatible with the data.

Double-Blind Period: Percentage of Relapse-Free Participants

• Endpoint type: Binary: the percentage of participants with the event (counts rebuilt from the posted percentages and group sizes).
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • Double-Blind: Laquinimod 0.3 mg: 70.0% (56/80) versus 64.1% (25/39) on control; risk difference 5.9 percentage points (95% CI -12.2 to 24.0), risk ratio 1.09 (0.83–1.44); unadjusted two-proportion z-test p = 0.517.
  • Double-Blind: Laquinimod 0.6 mg: 68.1% (64/94) versus 64.1% (25/39) on control; risk difference 4.0 percentage points (95% CI -13.8 to 21.7), risk ratio 1.06 (0.81–1.39); unadjusted two-proportion z-test p = 0.657.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Double-Blind: Laquinimod 0.3 mg and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Double-Blind: Laquinimod 0.6 mg and the control. The interval gives the range of effects that remain compatible with the data.

Double-Blind Period: Number of Enhancing Lesions on T1-Weighted Images

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Double-Blind: Laquinimod 0.3 mg: mean 2.50 versus 2.64 on control; difference -0.14 (95% CI -1.96 to 1.68), standardized effect d = -0.03; z-test p = 0.880.
  • Double-Blind: Laquinimod 0.6 mg: mean 2.18 versus 2.64 on control; difference -0.46 (95% CI -2.33 to 1.41), standardized effect d = -0.09; z-test p = 0.630.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Double-Blind: Laquinimod 0.3 mg and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Double-Blind: Laquinimod 0.6 mg and the control. The interval gives the range of effects that remain compatible with the data.

The registry lists secondary outcomes covering confirmed relapses, relapse-free participants, and magnetic resonance imaging findings, including enhancing lesions and T2 measures. The posted summaries are descriptive by group, and the recalculated comparisons do not show a consistent pattern of clearly separated estimates across these different types of outcomes. The intervals available for the posted comparisons include no difference. No inferential analyses are reported by the registry for the secondary outcomes.

These outcomes complement the primary safety endpoint by describing clinical disease activity and imaging findings during the double-blind period. They address different questions and have different measurement scales. A participant count, a mean relapse count, a proportion without relapse, and a lesion count should not be treated as interchangeable outcomes. Nor should a pattern in one measure be taken as a substitute for evidence on another.

The secondary results do not change the interpretation of the primary safety endpoint. They provide additional descriptive context, but do not establish that any observed difference is attributable to study treatment. The extension design and prior treatment histories remain relevant, and the registry does not report adjusted analyses that would account for those histories.

General statistical context: when many outcomes are examined, some apparent differences may occur by chance even if there is no underlying difference. An unadjusted p-value does not account for the number of outcomes or comparisons. Since the registry does not report a multiplicity strategy or sponsor-reported inferential analyses, the secondary calculations carry less evidential weight than a prespecified, appropriately adjusted analysis would. They are best regarded as exploratory descriptions of the posted data, not confirmatory findings.

Outcome denominators also vary, and the registry record does not explain the differences in available sample sizes or report how missing observations were handled. That limits interpretation of patterns across outcomes: a result from one subset may not directly represent the same participants contributing to another endpoint. Overall, the secondary data offer a broad view of observed outcomes but do not provide a firm basis for ranking groups or drawing conclusions about treatment effects.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Double-Blind Period: Relapse Rate: Total Number of Confirmed Relapses
• Double-Blind Period: Percentage of Relapse-Free Participants
• Double-Blind Period: Number of Enhancing Lesions on T1-Weighted Images
• Double-Blind Period: Number of New T2 Lesions
• Double-Blind Period: Volume of T2 Lesions
• Double-Blind Period: Number of New Hypointense T1 Lesion on Enhanced T1 Scans
• Double-Blind Period: Kurtzke's Expanded Disability Status Scale (EDSS) Score

9. Statistical Interpretation

10. Statistical Methods Explained

Outcome type and comparison

The primary outcome is a count of participants who experienced an adverse event. Although the result is expressed as a count, the comparisons treat the outcome as binary at the participant level: each person either had at least one adverse event during the endpoint period or did not. This differs from an event-rate analysis, which would account for multiple event episodes or time at risk. The registry does not report a recurrent-event analysis for the primary endpoint.

The posted risk difference compares the proportion with an event in one group with the proportion in the reference group. A positive value means the observed event proportion was higher in the named comparison group than in the reference group; a negative value would mean it was lower. The risk difference is expressed as a proportion, not as an odds ratio. A confidence interval describes a range of values compatible with the data under the calculation’s assumptions. When the interval includes zero, the data are compatible with no difference as well as with differences in either direction.

The record also gives unadjusted p-values for the calculated comparisons. A p-value evaluates how incompatible the data are with a specified no-difference model, under the model’s assumptions. It does not measure the probability that a treatment works, establish causality, or quantify the clinical importance of a difference. These p-values are unadjusted, and the registry does not list sponsor-reported analyses for the primary outcome.

How to read the treatment groups

The reference group for the primary comparisons is participants assigned placebo in LAQ/5062 and then laquinimod 0.3 mg in the extension. The continuation groups had received active laquinimod in LAQ/5062 before continuing their assigned doses. As a result, the contrast between a continuation group and a former-placebo group includes different treatment histories. Randomization in the extension applied to participants previously assigned placebo; the registry description does not indicate that all four posted groups were newly randomized against one another at extension entry.

This design distinction is important when interpreting the calculated comparisons. The former-placebo participants assigned two different extension doses form the closest concurrent randomized contrast described by the record. Comparisons involving those participants and people continuing active treatment should not be treated as if treatment history were identical across groups. The registry does not report adjusted analyses addressing prior treatment or other baseline differences.

Continuous secondary outcomes

The registry reports means and standard deviations for confirmed relapse counts and enhancing lesions. A mean gives the average observed count in a group; the standard deviation describes how dispersed individual values are around that average. A standard deviation is not a confidence interval for the mean and does not indicate the precision of a treatment comparison on its own.

The posted recalculations compare group means and give confidence intervals and unadjusted p-values. These are summary-statistic comparisons, not reported sponsor analyses. For count outcomes, values may be unevenly distributed, with many participants having low counts and a smaller number having higher counts. General statistical context: such distributions can depart from the assumptions of a simple normal model, and over-dispersion means observed variability is greater than a model expects. The registry record does not report whether the sponsor assessed distributional assumptions or used a count-specific model.

The relapse outcome is a total number of confirmed relapses over the stated double-blind period, reported as a mean with standard deviation. The imaging outcome is a mean number of enhancing lesions at the end of the active double-blind phase or termination visit, up to Week 36. The registry lists other imaging endpoints as well, but it does not provide reported inferential analyses for them in the record summarized by these results.

Missingness, multiplicity, and analysis populations

Outcome sample sizes differ across the primary and secondary summaries. For example, the primary safety counts use groups of 80, 94, 39, and 44, while the enhancing-lesion summaries use 66, 82, 36, and 38. Different outcome populations can arise when an outcome is not available for every participant, but the specific reasons for these denominators are not reported in the registry record. The missing-data rules, handling of incomplete follow-up, and methods for participants who discontinued early are also not reported in the registry record.

The registry lists multiple secondary outcomes, including relapse and imaging measures. Testing several outcomes can increase the chance that at least one result appears noteworthy by chance. General statistical context: multiplicity adjustments are used in some analyses to control this issue, but the record does not report whether adjustment was planned or performed. The posted secondary p-values are explicitly unadjusted recalculations, so they should not be treated as confirmatory evidence.

The record defines the primary safety analysis population as participants who entered the extension after completing LAQ/5062 and received at least one dose during the double-blind extension. It does not report a full statistical analysis plan, interim-analysis methods, a sample-size justification, or detailed rules for the secondary analysis populations. The absence of reported methods does not show that a method was not used; it means the method cannot be established from the registry record.

11. Confidence Intervals and Precision

The primary comparison intervals are wide enough to include no difference and values in either direction. For continuing laquinimod 0.3 mg compared with the placebo/laquinimod 0.3 mg group, the recalculated risk-difference interval extends from a negative value to a positive value. The same is true for the comparisons involving continuing laquinimod 0.6 mg and placebo/laquinimod 0.6 mg. The registry’s unadjusted p-values for these comparisons are 0.181, 0.210, and 0.186, respectively.

These intervals express uncertainty about the size and direction of the differences. They do not prove that the groups have the same event frequency. Nor do they identify a single value as the true effect. A wide interval can remain compatible with potentially meaningful differences even when the point estimate is on one side of zero. Precision depends on the amount and variability of information in the data, as well as on the analysis method.

Group sizes for the primary comparisons range from 39 to 94 participants. The relatively limited group sizes are relevant context for interpreting the uncertainty, but do not by themselves determine the amount of precision. For secondary comparisons, some posted confidence intervals are also broad and include no difference. They are unadjusted calculations, and the registry does not report sponsor analyses that could provide a separate adjusted estimate.

General statistical explanation: a confidence interval is a procedure that, under its assumptions, produces ranges that capture the target parameter at a stated long-run frequency. It is not a probability statement about the fixed effect in this particular study. The registry record does not report the confidence level as part of a sponsor analysis; the intervals discussed for comparisons are unadjusted recalculations from the posted summary statistics.

Precision should also be distinguished from bias and applicability. Narrower uncertainty alone would not correct differences in prior treatment history, missing outcome data, or other design limitations. Here, the double-blind continuation groups and former-placebo groups have distinct treatment histories, and reasons for differing outcome denominators are not reported. Therefore, interval width is only one part of assessing how much the results can establish.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The planning figures are illustrations based on observed effects, not the extension study’s original enrollment plan. For the binary participant-with-an-event outcome, the figures are participants per arm. For the continuous outcomes, they are also participants per arm. The general assumption listed for these calculations is two-sided significance level 0.05, equal allocation between the two arms, and a normal approximation. The effect to detect is the stated fraction of the observed effect.

The 80% power column describes the number of participants per arm in a hypothetical study that, under those assumptions and for the specified effect, would have an 80% chance of producing a statistically significant result. The 90% power column describes the corresponding hypothetical target for a 90% chance. These are planning interpretations, not guarantees about a future study’s outcome. The trial’s own original design assumptions and sample-size justification are not reported in the registry record.

Each planning scenario uses either 100%, 75%, or 50% of the observed effect as the effect to detect. A smaller assumed effect requires more participants to distinguish it from random variation under the same calculation assumptions. Some estimates are extremely large because the observed difference used as the planning basis is small relative to the variation in the data. Such outputs should be understood as illustrations of the information needed under the stated assumptions, not as proof that a study of that size would be feasible or appropriate.

These figures are not observed power. Observed power is not a useful substitute for examining the estimated effect and its uncertainty after a study has been completed. The planning values instead answer a prospective question: what sample size would a hypothetical equally allocated comparison need for a chosen power target, given the stated effect and assumptions? The registry does not report that these assumptions were used to design LAQ/5063.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, p₀ and p₁ are the control and treatment proportions, and p̄ is their average.

Worked calculation for this trial

1. Control proportion p₀ = 0.590; treatment proportion p₁ = 0.713; average p̄ = 0.651.
2. First term: z_1−α/2 × √[2p̄(1−p̄)] = 1.96 × 0.6740 = 1.3211.
3. Second term: z_1−β × √[p₀(1−p₀) + p₁(1−p₁)] = 0.842 × 0.6684 = 0.5626.
4. n = (1.3211 + 0.5626)² / (0.1228)² = 235.5, rounded up to 236 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
p0 <- 0.58974358974359                          # control proportion
p1 <- 0.7125                          # treatment proportion
n_per_arm <- function(power, frac = 1) {
  q1 <- p0 + (p1 - p0) * frac               # smaller effect = fraction of the observed difference
  pbar <- (p0 + q1) / 2
  z_b <- qnorm(power)
  ceiling(round((z_a * sqrt(2 * pbar * (1 - pbar)) + z_b * sqrt(p0 * (1 - p0) + q1 * (1 - q1)))^2 / (q1 - p0)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (unrounded n per arm)
cat("power.prop.test:", round(power.prop.test(p1 = p0, p2 = p1, power = 0.80)$n, 1), "\n")

# Simulation: how often does the z-test reject at the 80%-power sample size?
set.seed(745615)
n    <- n_per_arm(0.80)
reps <- 20000
x0 <- rbinom(reps, n, p0); x1 <- rbinom(reps, n, p1)
ph <- (x0 + x1) / (2 * n)
z  <- ((x1 - x0) / n) / sqrt(ph * (1 - ph) * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(z) > z_a, na.rm = TRUE), reps))

Output from running the code

100% of observed effect: n per arm = 236 (80% power), 315 (90% power)
 75% of observed effect: n per arm = 428 (80% power), 573 (90% power)
 50% of observed effect: n per arm = 981 (80% power), 1,312 (90% power)
power.prop.test: 235.5 
Simulated power at n = 236 per arm: 0.807 (20000 replicates)

The simulation draws many pairs of event counts at the planned sample size and counts how often the two-proportion z-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Multiplicity, Missing Data and Analysis Populations

The registry identifies numerous secondary outcomes, including relapse measures and several magnetic resonance imaging measures. It does not report whether the statistical plan used a hierarchy of endpoints, a multiplicity adjustment, or another strategy to manage the consequences of multiple comparisons. The posted recalculations are unadjusted. When multiple outcomes and contrasts are examined, the chance of at least one apparently notable result can increase. General statistical context: adjustment or prespecified testing order can help address this issue, but whether such methods were used cannot be established from the registry record.

The registry record also does not report a detailed missing-data plan. It does not state how incomplete observations, early termination, or withdrawal were handled in the endpoint analyses. The analysis population for the primary safety outcome is defined as participants who entered the extension after completing LAQ/5062 and received at least one dose during the double-blind phase. The record does not provide equivalent detailed population definitions for every secondary outcome.

Group denominators differ across outcomes. The primary safety endpoint includes 80, 94, 39, and 44 participants in its four groups, while the enhancing-lesion outcome includes 66, 82, 36, and 38. The record does not explain the reasons for these differences. Missingness can affect interpretation if the availability of an outcome is related to participant characteristics, treatment history, or outcome values; whether that occurred in this study is not reported in the registry record.

No sponsor-reported analyses are listed for the posted endpoints. The registry record does not report whether interim analyses were conducted, whether any adjustment was applied to the primary or secondary comparisons, or what analysis populations were planned for each outcome. It also does not report a statistical analysis plan or the original sample-size justification. These gaps limit the ability to assess whether the displayed comparisons correspond to the study’s planned analyses. They should be treated as absent information, not evidence that a particular procedure was or was not used.

15. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: chronic tonsillitis (2.1%), cholecystitis acute (1.8%), arthralgia (1.8%), leukocytosis (1.0%), acute myocardial infarction (1.0%).

The serious adverse-event summaries are presented by treatment period and group. In the double-blind summaries, 6 of 119 participants in the laquinimod 0.3 mg/placebo-to-laquinimod 0.3 mg group and 6 of 138 in the laquinimod 0.6 mg/placebo-to-laquinimod 0.6 mg group had serious adverse events. In the open-label groups, 30 of 113 participants receiving laquinimod 0.6 mg and 19 of 96 participants moving from laquinimod 0.3 mg to 0.6 mg had serious adverse events. The open-label 0.6 mg group had 2 deaths recorded; the other listed groups had 0.

These are counts of participants with serious events in the registry’s adverse-event summaries. They are not comparative causal estimates, and the groups do not all represent the same treatment period or treatment history. The open-label phase has no concurrent randomized comparator. The registry lists serious-event terms including chronic tonsillitis at 2.1%, acute cholecystitis at 1.8%, arthralgia at 1.8%, leukocytosis at 1.0%, acute myocardial infarction at 1.0%, and cardiomyopathy at 1.0%.

The adverse-event definition does not require a causal relationship to study drug. The counts therefore describe events recorded during the study, not events established as caused by treatment. The registry record does not provide enough information in these summaries to compare event timing, exposure duration, or individual circumstances across groups.

16. What the Result Does, and Does Not, Mean

The results establish what the registry posts: adverse-event counts in the double-blind extension groups, descriptive summaries for several secondary outcomes, and serious-event summaries across double-blind and open-label periods. They also show the uncertainty surrounding the unadjusted comparisons. The primary comparisons have confidence intervals that include no difference, and the registry does not list a sponsor-reported inferential analysis for the primary endpoint.

That pattern is not evidence that the groups are equivalent. Demonstrating equivalence or non-inferiority requires an appropriate prespecified design and analysis, including a defined margin; those details are not reported in the registry record. Conversely, observed differences in counts do not by themselves establish a causal treatment effect. The posted calculations are unadjusted and the groups differ in prior treatment history.

The primary endpoint captures whether a participant had at least one adverse event, not the full burden, severity, duration, or recurrence of all events. Serious-event summaries add information about events meeting the registry’s seriousness definition, but do not establish causality. The open-label observations are particularly difficult to compare causally because participants knew they were receiving laquinimod and there was no concurrent randomized placebo group in that phase.

The secondary outcomes are also limited in what they can establish. They cover relapse and imaging measures, but the registry record does not report sponsor analyses or a multiplicity plan. Their posted summaries and recalculations are therefore descriptive and exploratory. Different sample sizes across outcomes and unreported missing-data methods further restrict cross-outcome comparisons.

The trial is an extension of an earlier study, not an independent comparison beginning with a common treatment history for every group. Participants in active-treatment arms continued their assigned treatment, while former placebo participants were assigned to laquinimod doses. This structure is essential to understanding what the comparisons represent. The record is also marked terminated, but the reasons for termination are not reported in the registry record.

Accordingly, the posted data can be used to understand the observed counts and the limits of their precision. They cannot support a broad conclusion about the causal effect of laquinimod, establish that groups are the same, or replace a complete statistical analysis plan and sponsor-reported analyses.

17. Why This Trial Matters Statistically

This study illustrates a recurring challenge in extension trials: a randomized, blinded phase can include groups with different histories from the earlier study. Participants continuing active treatment and participants who previously received placebo do not enter the extension with the same treatment exposure. A treatment label alone is therefore not enough to understand a comparison; the sequence of assignments matters.

The primary outcome is a participant-level safety count, while the secondary outcomes include relapse and imaging measures. They answer different questions and use different outcome scales. Keeping endpoint definitions distinct helps prevent a count of affected participants from being confused with a mean number of events or with a percentage of participants meeting a condition.

The record also demonstrates why uncertainty matters alongside point estimates. The calculated primary comparisons have intervals that include no difference, and the registry does not report inferential analyses from the sponsor. The group counts can describe the observed study experience, but they do not establish a definitive comparative effect. The same caution applies to secondary outcomes with unadjusted calculations and no reported multiplicity plan.

Finally, this record makes visible the limits of registry reporting. Important details, including the original sample-size rationale, missing-data handling, and statistical analysis plan, are not reported in the registry record. Recognizing those gaps is part of statistical interpretation: it distinguishes what the posted observations directly describe from conclusions that require methods or analyses not reported in the record.

18. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main design limitation for interpretation is the extension’s differing treatment histories. Participants continuing active laquinimod from LAQ/5062 are not exchangeable by design with participants assigned laquinimod after receiving placebo in the earlier study. The registry does not report adjusted comparisons accounting for treatment history or other participant characteristics.

The primary outcome is a count of participants with one or more adverse events, which does not convey the number of events per person, duration, severity beyond the serious-event classification, or time to first event. The record does not report exposure-adjusted event rates for the primary endpoint. The adverse-event definition includes occurrences without regard to a possible causal relationship, so these totals should not be interpreted as drug-caused events.

The record is marked terminated, and the open-label phase continued only while the sponsor continued development or until early discontinuation. The reason for termination and the completeness of follow-up are not reported in the registry record. The open-label phase is not randomized against a concurrent placebo group, and its summaries should not be treated as direct comparative estimates.

Outcome denominators vary, including between the primary safety endpoint and imaging outcomes. The reasons for these differences and the missing-data procedures are not reported in the registry record. The registry also does not report the original sample-size justification, detailed analysis plan, or whether interim analyses were conducted. It lists multiple secondary outcomes but does not report multiplicity handling or sponsor-reported inferential analyses. Together, these omissions make it difficult to determine how closely the posted summaries reflect the originally planned analyses.

19. Related Tutorials

20. Related Statistical Calculators

21. Sources

• ClinicalTrials.gov: An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease — NCT00745615.
• Registry record last updated 2019-03-27; status last verified 2019-03.
• Results first posted 2019-03-27.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

22. Record Summary

NCT00745615 is a randomized, double-blind, parallel-group Phase 2 active extension study in relapsing remitting multiple sclerosis. The registry lists 257 enrolled participants and a terminated status. During the blinded extension, participants continued prior active laquinimod assignments or, if previously assigned placebo, were randomized to laquinimod 0.3 mg or 0.6 mg. The study then continued in an open-label phase with laquinimod 0.6 mg daily.

The primary endpoint was the number of participants with adverse events from baseline to Week 36. The posted counts describe events in the four double-blind groups; recalculated unadjusted comparisons have confidence intervals including no difference. The registry lists secondary relapse and imaging outcomes but no reported analyses for them. Reasons for termination, the original sample-size justification, detailed missing-data methods, and the statistical analysis plan are not reported in the registry record.